La eficacia de Sacubitrilo/Valsartán en el tratamiento de la insuficiencia cardiaca
Article Sidebar
Main Article Content
Abstract
Objective: To analyze the standard treatment of Heart Failure compared to Sacubitril-Valsartan, in order to understand the patients who may benefit from this aforementioned drug. Methods: The methodological approach of this work proposes a compilation of bibliographic research with a qualitative approach and descriptive character through an integrative review of the literature in the electronic databases National Library of Medicine, Directory of Open Access Journals and Virtual Health Library. The descriptors used were: “Sacubitril Valsartan”, “Heart Failure” and “Treatment Effectiveness”. Inclusion criteria were controlled clinical trial, articles in English, free and full text and articles published between 2019 and 2022. Results: The drug Sacubitril/Valsartan was compared with Enalapril, Valsartan and other drugs in the treatment of Heart Failure. The results of the selected studies were evaluated and a comparative table was constructed, which is composed of the number of individuals approached in the studies, year of publication, the patients who were selected for the study, main benefits of sacubitril/valsartan in relation to other drugs and reaction adverse effects and/or harm compared to other drugs. Final considerations: Thus, a great benefit of Sacubitril-Valsartan was observed for patients with HF, compared to the standard treatment of this disease.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BALMFORTH C, et al. Resultados e Efeitos do Tratamento Segundo a Etiologia na ICFEr: Uma Análise do PARADIGM-HF. JACC Heart Fail, 2019; 457–465
3. BHATT AS, et al. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial. European J of Heart Fail, 2021; 23(9): 1518–1524.
4. CHANG HY, et al. Sacubitril/valsartana em pacientes com insuficiência cardíaca com fração de ejeção reduzida: experiência do mundo real em doença renal crônica avançada, hipotensão e aumento da dose. Journal of Cardiology, 2019; 74(4): 372–380.
5. CHEN DY, et al. Resultados clínicos de Sacubitril/Valsartan em pacientes com insuficiência cardíaca aguda: Um estudo multi-institucional. EClinicalMedicine, 2021; 41: 101149.
6. CUNNINGHAM JW, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020; 8(5): 372–381.
7. FUDIM M, et al. Representatividade da População do Ensaio Clínico PIONEER-HF em Pacientes Hospitalizados com Insuficiência Cardíaca e Fração de Ejeção Reduzida. Circulação: Insuficiência Cardíaca, 2020; 13(4): e006645.
8. GORI M, et al. Evidência de superioridade de sacubitril/valsartan versus inibidores da enzima conversora de angiotensina ou bloqueadores de receptores de angiotensina ii na insuficiência cardíaca com jornada do paciente com fração de ejeção reduzida. Cardiology Plus, 2021a; 6(1): 23–29.
9. GORI M, et al. Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2021b; 7.
10. HADDAD H, et al. Experiência Canadense do Mundo Real do Uso de Sacubitril/Valsartana em Pacientes com Insuficiência Cardíaca com Fração de Ejeção Reduzida: Insight do Estudo PARASAIL. CJC Open, 2020; 2(5): 344–353.
11. JACKSON AM, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J, 2021; 42(36): 3741–3752.
12. KIDO K, et al. Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Ann Pharmacother 2021; 55(9): 1069–1075.
13. LELONEK M, et al. Sacubitril/valsartan para insuficiência cardíaca com fração de ejeção reduzida: Um primeiro estudo observacional da vida real na Polônia. Advances in Clinical and Experimental Medicine, 2021; 30(1): 67–75.
14. MANN DL, et al. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail, 2020; 8(10): 789–799.
15. MARQUES SP, AGUIAR C. Sacubitril/valsartan: um avanço importante no enigma terapêutico da operação cardíaca. Rev Port Cardiol, 2017; 36(9): 655–668.
16. HOSPITAL DAS CLÍNICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (HCFMUSP). Medicina de Emergência: Abordagem Prática. Manole, 2021; (15): 1736.
17. MITCHELL GF, et al. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study. Circulation: Heart Failure, 2021; 14(3): e007891.
18. MORROW DA, et al. Biomarcadores cardiovasculares em pacientes com insuficiência cardíaca aguda descompensada randomizados para sacubitril-valsartana ou enalapril no estudo PIONEER-HF. Eur Heart J, 2019; 3345–3352.
19. PANG Z, et al. A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial. Medicine (Baltimore), 2021; 100(16): e25621.
20. PATHADKA S, et al. Hospitalização e Mortalidade em Pacientes com Insuficiência Cardíaca Tratados com Sacubitril/Valsartana vs. Enalapril: Um Estudo Populacional do Mundo Real. Fronteiras em Medicina Cardiovascular, 2021; 7.
21. ROHDE LEP, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq. Bras. Cardiol., 2018; 111(3).
22. SELVARAJ S, et al. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol, 2020; 75(14): 1644–1656.
23. SOLOMON SD, et al. Sacubitril/Valsartana no Espectro da Fração de Ejeção na Insuficiência Cardíaca. Circulação, 2020; 141(5): 352–361.
24. STEPHEN J, et al. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021; 10(16): e021459.
25. TSUTSUI H, et al. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction ― Results From the PARALLEL-HF Study ―. Circulation Journal, 2021; 85(5): 584–594.
26. VADUGANATHAN M, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol, 2020; 75(3): 245–254.
27. VARDENY O, et al. Redução do uso de diuréticos de alça em pacientes tomando sacubitril/valsartana em comparação com enalapril: o estudo PARADIGM-HF. Eur J Heart Fail, 2019; 21(3): 337–341.